Variants in the 15q24/25 Locus Associate with Lung Function Decline in Active Smokers

Genetic variation in nicotinic acetylcholine receptor subunit genes (nAChRs) is associated with lung function level and chronic obstructive pulmonary disease (COPD). It is unknown whether these variants also predispose to an accelerated lung function decline. We investigated the association of nAChR...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 1; p. e53219
Main Authors Mohamed Hoesein, Firdaus A A, Wauters, Els, Janssens, Wim, Groen, Harry J M, Smolonska, Joanna, Wijmenga, Cisca, Postma, Dirkje S, Boezen, H Marike, De Jong, Pim A, Decramer, Marc, Lammers, Jan-Willem J, Lambrechts, Diether, Zanen, Pieter
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 18.01.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Genetic variation in nicotinic acetylcholine receptor subunit genes (nAChRs) is associated with lung function level and chronic obstructive pulmonary disease (COPD). It is unknown whether these variants also predispose to an accelerated lung function decline. We investigated the association of nAChR susceptibility variants with lung function decline and COPD severity. The rs1051730 and rs8034191 variants were genotyped in a population-based cohort of 1,226 heavy smokers (COPACETIC) and in an independent cohort of 883 heavy smokers, of which 653 with COPD of varying severity (LEUVEN). Participants underwent pulmonary function tests at baseline. Lung function decline was assessed over a median follow-up of 3 years in COPACETIC. Current smokers homozygous for the rs1051730 A-allele or rs8034191 G-allele had significantly greater FEV(1)/FVC decline than homozygous carriers of wild-type alleles (3.3% and 4.3%, p = 0.026 and p = 0.009, respectively). In the LEUVEN cohort, rs1051730 AA-carriers and rs8034191 GG-carriers had a two-fold increased risk to suffer from COPD GOLD IV (OR 2.29, 95% confidence interval [CI] = 1.11-4.75; p = 0.025 and OR = 2.42, 95% [CI] = 1.18-4.95; p = 0.016, respectively). The same risk alleles conferred, respectively, a five- and four-fold increased risk to be referred for lung transplantation because of end-stage COPD (OR = 5.0, 95% [CI] = 1.68-14.89; p = 0.004 and OR = 4.06, 95% [CI] = 1.39-11.88; p = 0.010). In Europeans, variants in nAChRs associate with an accelerated lung function decline in current smokers and with clinically relevant COPD.
Bibliography:Competing Interests: DS Postma received funding for research from AstraZeneca, GSK, Nycomed. Travel to ERS or ATS has been partially funded by AstraZeneca, GSK, Chiesi, Nycomed. DS Postma has been consultant to AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Nycomed, TEVA. W Janssens has been consultant and received travel grants from Boehringer Ingelheim, Astra Zeneca, Nycomed. All the other authors state that they have no conflicts of interests. The above commercial funding was not for this specific study. This study was, however, funded by ‘Zorg Onderzoek Nederland-Medische Wetenschappen, KWF Kankerbestrijding, Stichting Centraal Fonds Reserves van Voormalig Vrijwillige Ziekenfondsverzekeringen, Siemens Germany, G. Ph. Verhagen Stichting, Rotterdam Oncologic Thoracic Steering Committee, Erasmus Trust Fund, Stichting tegen Kanker. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Conceived and designed the experiments: PZ WJ DL. Performed the experiments: JS EW. Analyzed the data: FMH EW PZ WJ DL. Contributed reagents/materials/analysis tools: JS. Wrote the paper: FMH EW PZ WJ DL HG CW DP MB PDJ MD JL.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0053219